SCHEMBL144707

SCHEMBL144707

Cc1cc(-c2ccc(C(=O)O)cc2)c(/C=C2\C(=O)Nc3ccc(S(=O)(=O)Cc4ccccc4)cc32)[nH]1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 3/20 0.53
ALK Q9UM73 7/20 0.53
PAK4 O96013 1/20 0.49
TLK2 Q86UE8 1/20 0.48
FLT1 P17948 3/20 0.46
KDR P35968 8/20 0.45
FGFR1 P11362 6/20 0.45
PDGFRB P09619 5/20 0.45
TSHR P16473 2/20 0.45
HSD17B10 Q99714 1/20 0.45
EGFR P00533 1/20 0.45
PDPK1 O15530 2/20 0.44
SRC P12931 3/20 0.44
CSF1R P07333 2/20 0.44
RET P07949 2/20 0.44
FGFR3 P22607 2/20 0.44
MAPK1 P28482 2/20 0.44
FLT4 P35916 2/20 0.44
FLT3 P36888 2/20 0.44
MEN1 O00255 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6519857 0.87 AURKA (0.56) AURKAALKPAK4TLK2FLT1
SCHEMBL141995 0.85 RET (0.61) AURKAALKPAK4TLK2FLT1
SCHEMBL143571 0.81 ALK (0.63) AURKAALKTLK2KDRFGFR1
SCHEMBL6258070 0.80 ALK (0.57) AURKAALKPAK4TLK2FLT1
SCHEMBL6523443 0.79 RET (0.49) AURKAALKTLK2FLT1KDR
SCHEMBL6514860 0.79 AKT2 (0.58) AURKAKDRFGFR1PDGFRBEGFR
SCHEMBL144133 0.78 KDR (0.63) AURKAALKFLT1KDRFGFR1
SCHEMBL6333460 0.78 AURKA (0.53) AURKAALKKDRFGFR1PDGFRB
SCHEMBL147260 0.77 FGFR1 (0.76) AURKAALKFLT1KDRFGFR1
SCHEMBL6515665 0.77 FLT1 (0.47) AURKAALKPAK4TLK2FLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6599902-B2 For treating or preventing a protein kinase related disorder SUGEN, INC. 2003-07-29 US claimed
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS SUGEN, INC. 2003-07-03 US claimed
US-20140221455-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR Verva Pharmaceuticals, Inc. (AU) 2014-08-07 US disclosed
US-20120059047-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR VERVA PHARMACEUTICALS PTY LTD (AU) 2012-03-08 US disclosed
US-20050282733-A1 Differentiation modulating agents and uses therefor VERVA PHARMACEUTICALS PTY LTD (AU) 2005-12-22 US disclosed
WO-2005065686-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR ADIPOGEN PHARMACEUTICALS PTY LIMITED (AU) 2005-07-21 WO disclosed
US-6599902-B2 For treating or preventing a protein kinase related disorder SUGEN, INC. 2003-07-29 US disclosed
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS SUGEN, INC. 2003-07-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120059047-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR FGF1, FABP4, FGF2 AURKA 4579/4885ALK 3814/4885PAK4 482/4885
US-20050282733-A1 Differentiation modulating agents and uses therefor FGF1, FABP4, FGF2 AURKA 4579/4885ALK 3814/4885PAK4 482/4885
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS DMPK, ADK, MAP3K20 AURKA 273/4885ALK 327/4885PAK4 207/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.